Postmenopausal choriocarcinoma: a rare case report and review of the literature

Menopause. 2018 Feb;25(2):239-241. doi: 10.1097/GME.0000000000000968.

Abstract

Objective: Choriocarcinoma is rare in postmenopausal women, and an early diagnosis contributes to a potential cure.

Methods: We report a rare case of a postmenopausal woman with choriocarcinoma. The 61-year-old patient presented with irregular vaginal bleeding, 11 years after menopause and 30 years after the birth of the last child.

Results: Radiological investigation found a 3-cm mass on the lower left part of the vaginal wall, and also bilateral lung nodules. Gynecological examination found 3-4 cm blue and purple nodules in the lower left part of the vaginal wall. Her serum CA125 and serum β-hCG levels were 10.2 and 9273.9 mIU/mL, respectively. The early diagnosis was a choriocarcinoma, and combination chemotherapy (etoposide, kengshengmycin, methotrexate, leucovorin, vincristine, and cyclophosphamide [EMACO]) was administered. After the sixth chemotherapy session, her serum β-hCG level was <2 mIU/mL, and two additional consolidation chemotherapy sessions were performed. She achieved serological remission, but 4 months after completion of the chemotherapy, a rise in serum β-hCG level was observed. Therefore, she was subjected to a second treatment with EMACO and fluorouracil (5-Fu) local injection chemotherapy. After nine chemotherapy sessions and three local 5-Fu injections, she showed a normal β-hCG level, with negative radiological results, and negative pigmentation in the lower left part of the vaginal wall. After a 4-year follow-up period, no local recurrence or distant metastases was found.

Conclusions: This patient has shown a mild response to chemotherapy when compared with patients in reproductive age, and the combination of standard chemotherapy with local injection chemotherapy may be helpful for treating similar clinical cases.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Choriocarcinoma / diagnostic imaging
  • Choriocarcinoma / drug therapy*
  • Choriocarcinoma / secondary
  • Chorionic Gonadotropin, beta Subunit, Human / blood
  • Cyclophosphamide / therapeutic use
  • Dactinomycin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Methotrexate / therapeutic use
  • Middle Aged
  • Postmenopause
  • Vaginal Neoplasms / diagnostic imaging
  • Vaginal Neoplasms / drug therapy*
  • Vaginal Neoplasms / pathology
  • Vincristine / therapeutic use

Substances

  • Chorionic Gonadotropin, beta Subunit, Human
  • Dactinomycin
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • EMA-CO protocol